Diabetes Clinical Trials in Seattle
View 57 new treatments for Diabetes in Seattle, WA, and nearby areas, such as Bellevue, Everett, Kent and Renton. Every day, Power helps hundreds of diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
GIK Therapy for High Blood Sugar During Surgery
Research Clinic, Seattle + 1 more
The PATCH pilot trial aims to establish feasibility and determine the sample size of a future, large-scale, multi-site RCT, as well as reinforce the long-standing known safety profile of glucose, insulin, and potassium (GIK) and explore the physiologic response. We hypothesize that the use of GIK in non-diabetic patients undergoing abdominal surgery, will reduce rates of morbidity \& death compared to standard of care treatment. In brief, primary outcomes of interest include estimation of the standard deviation (to derive a sample size estimation) and the ability to recruit target population, assessment of patient compliance/burden, and assessment of provider compliance/burden (feasibility).Show More
Waitlist
Phase 4
Est. 3 - 6 Weeks
David Flum, MD, MPH
Principal Investigator
Teplizumab for Pediatric Type 1 Diabetes
Provention Bio Clinic, Tacoma + 2 more
This trial tests the safety of teplizumab, an IV medication, in children under 8 with early signs of type 1 diabetes. The drug aims to protect insulin-producing cells from immune system attacks and has shown potential in delaying the onset of type 1 diabetes.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Provention Bio, Inc., MD
Study Director
Mifepristone for Type 2 Diabetes
Corcept Clinic, Seattle + 1 more
This trial is testing mifepristone, a medication that blocks cortisol, in patients with hard-to-control type 2 diabetes and high cortisol levels. The goal is to see if mifepristone can help manage their blood sugar better than standard treatments alone. Mifepristone has been studied for various conditions including Cushing's syndrome, psychotic depression, and cognitive decline in Alzheimer's disease.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Daniel Einhorn, MD
Study Director
Semaglutide for Type 2 Diabetes
Research Clinic, Seattle + 1 more
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication. Given the available evidence supporting the neuroprotective effect of this drug class and stroke reduction with semaglutide, and the investigators preliminary data showing that T2D had significantly reduced total number of distal arterial branches in the brain than non-T2D, the investigators expect treatment with semaglutide will be associated with improved intracranial blood flow condition.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Francis Kim, MD
Principal Investigator
Pentoxifylline for Diabetic Kidney Disease
Research Clinic, Seattle + 1 more
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
David J Leehey
Study Chair
Ranibizumab PDS Implant for Diabetic Retinopathy
Hoffmann-La Roche Clinic, Silverdale + 1 more
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Clinical Trials
Study Director
Orforglipron for Obesity
Eli Lilly Clinic, Tacoma + 1 more
This trial will test a daily pill called orforglipron to see if it helps people who are overweight or obese and have type 2 diabetes lose weight. The study will last over a year and involve multiple visits.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Suzetrigine for Diabetic Neuropathy
Vertex Clinic, Bellevue + 1 more
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
IcoSema for Type 2 Diabetes
Novo Nordisk Clinic, Port Orchard + 1 more
This trial will test a new weekly injection called IcoSema, which combines two drugs, in people with type 2 diabetes. The goal is to see if it controls blood sugar better than just using one of the drugs alone. Participants will receive either IcoSema or the single drug and will be monitored for several months.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Clinical Transparency (dept. 2834)
Study Director
BI 456906 for Diabetes and Obesity
Boehringer Ingelheim Clinic, Renton + 1 more
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Page 1 of 7
Frequently Asked Questions
Explore related conditions